Edwards Lifesciences' Projection of TAVR Adoption Rates in U.S. Turns Out To Be Too Rosy

Medtronic is not too far behind, although it has been hobbled by a slow-enrolling pivotal trial that finally closed in early January.

http://www.mddionline.com/article/edwards-lifesciences-projections-tavr-adoption-rates-us-turns-out-be-too-rosy